How to Buy Rapt Therapeutics Stock
Rapt Therapeutics Inc
RAPT Therapeutics, Inc. , a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.
Rapt Therapeutics stock last closed at $7.80, down 1.27% from the previous day, and has decreased 59.38% in one year. It has underperformed other stocks in the Biotechnology industry by 0.36 percentage points. Rapt Therapeutics stock is currently +13.7% from its 52-week low of $6.86, and -71.48% from its 52-week high of $27.35.
There are currently 34.8M RAPT shares outstanding. The market capitalization of RAPT is $271.42M. In the past 24 hours, 420,021 RAPT shares were traded.
How to Buy Rapt Therapeutics Stock
Not sure how to invest in Rapt Therapeutics stock? Here's how.
- Figure out where to buy Rapt Therapeutics stock: You need to pick a stock brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you decide where to buy Rapt Therapeutics stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit funds into your brokerage account: Pick your method of payment and add your info.
- Evaluate Rapt Therapeutics stock: The Rapt Therapeutics ticker symbol is RAPT. Is Rapt Therapeutics stock a good investment? Should you buy shares of RAPT? How do RAPT's underlying business fundamentals look? Do top analysts think Rapt Therapeutics is a good buy? Why has RAPT's stock price moved recently? (Hint: Our stock analysis website can help you understand if RAPT is a good stock to buy).
- Make your RAPT trade: Decide if you will purchase RAPT shares at the current market price or use a limit order to buy RAPT shares at a specific price.
- Get the latest news on your RAPT position: Create a watchlist to get the latest news on your new investment in Rapt Therapeutics stock.
Step 1: Figure out where to buy Rapt Therapeutics stock
You need an online brokerage account in order to access the NASDAQ market and buy RAPT stock.
Our preferred brokerage: eToro
In our opinion, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world markets: From Technology to Energy, New York to London — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by creating an account with eToro now.
Open eToro AccountStep 2: Create a brokerage account
Now that you've picked the best brokerage, you'll need to fill out some personal details so you can invest in RAPT stock today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to open your new brokerage account.
- Send your application by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've filled out your info on app for stock market, you need to deposit funds:
Watch the video below if you need help depositing money into your new investment account.
Step 4: Evaluate Rapt Therapeutics stock
Once you have selected the best place to buy Rapt Therapeutics stock, it's critical to analyze their stock prior to investing, so you can wrap your head around the risk and upside.
Rapt Therapeutics shares at a glance
RAPT Zen Score
WallStreetZen was designed to help average investors perform more in-depth fundamental analysis in less time.
You can view all of the due diligence checks on RAPT's stock page.
Is RAPT stock properly valued?
Investors use many financial metrics, analyses, models, and charts to gauge RAPT's true value.
Using relative valuations measures:
- RAPT could be undervalued based on its P/B ratio of 1.85x, relative to Biotechnology industry P/B ratio of 5.8x
You can do additional valuation research on RAPT's stock here.
RAPT Financial Health
Positive Health Checks:
- RAPT has a low debt to equity ratio of 0.18.
- There are more short-term assets than short-term liabilities on the RAPT balance sheet.
- RAPT has cash burn of 98173000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the RAPT balance sheet.
- Total RAPT debt is lower than 5 years ago, relative to shareholder equity.
Negative Health Checks:
- RAPT has $158.86M in cash and short term investments. This is not sufficient to cover its annual cash burn of $98.17M.
Do Wall Street analysts think it's a good time to buy Rapt Therapeutics stock
Out of 6 sell side analysts who give ratings on RAPT, the consensus analyst rating on Rapt Therapeutics is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they investment advice.
Latest RAPT Analyst Forecasts
Raghuram Selvaraju, a bottom 2% analyst from HC Wainwright & Co. reiterates RAPT with a buy rating and maintains their RAPT price target from $41.00 to $41.00, on Nov 15, 2023.
You can dig deeper into what analysts are projecting on the Rapt Therapeutics stock forecast page.
RAPT Trading Indicators
RAPT Earnings
Last year, RAPT revenue was $0.00. During the past 3 year, RAPT's revenue has increased by -100% per year. This was slower than the Biotechnology industry average of 28.62%.
Find out more about RAPT's earnings and revenue performance here.
Are RAPT insiders buying or selling the stock?
Over the past 12 months, executives and large shareholders at RAPT have sold more shares than they have bought.
Dirk G. Brockstedt, CHIEF SCIENTIFIC OFFICER of RAPT, was the latest RAPT insider to sell. They sold $20,456.44 worth of RAPT stock on Jan 5, 2024.
Get more info about who owns RAPT stock here.
Can I rely on RAPT as an income stream?
No, Rapt Therapeutics doesn't provide an income stream by paying out dividends.
What do other traders have to say about RAPT?
One of the reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your RAPT trade
You have two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are mostly the best for newer investors. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a specific price limit, use a limit order.
Hit the Open Trade button and eToro will place the order.
If you want additional help buying stocks on eToro, watch the how to video below:
Step 6: Get the latest news on your RAPT position
Now that you own some shares in RAPT, you'll want to stay up-to-date on your new shares.
Add RAPT to a watchlist to get alerted to the latest events about your RAPT stock.
RAPT Feed
How to Buy Stock in Rapt Therapeutics
To reiterate, here are the 6 steps to buy Rapt Therapeutics stock:
- Figure out where to buy Rapt Therapeutics stock
- Create a brokerage account
- Deposit funds into your brokerage account
- Evaluate Rapt Therapeutics stock
- Make your RAPT trade
- Get the latest news on your RAPT position
If you require a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you want to watch your new investment in Rapt Therapeutics, add RAPT to your watchlist by clicking the button below.
Other Content You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.